ANEUVO Launches US Study of ExaStim, a Non-invasive Spinal 2-02-2023, 22:36

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

KOORUI Launches Multi-Model Monitor Lineup Globally, Strengthening Its Presence in Key Markets 26-06-2025, 16:08